🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 17 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 29/01/2001 | 72,06 | 74,75 | 69,88 | 74,19 | +3,40% | 6,76% | 465.400 |
| 26/01/2001 | 66,81 | 72,44 | 66,25 | 71,75 | +4,36% | 9,26% | 582.800 |
| 25/01/2001 | 69,94 | 71,06 | 66,31 | 68,75 | -1,96% | 6,79% | 680.600 |
| 24/01/2001 | 68,25 | 75,17 | 68,19 | 70,13 | +1,63% | 10,23% | 1.565.100 |
| 23/01/2001 | 60,31 | 69,31 | 60,31 | 69,00 | +13,46% | 14,92% | 1.609.700 |
| 22/01/2001 | 56,81 | 62,00 | 56,75 | 60,81 | +5,99% | 9,24% | 1.103.400 |
| 19/01/2001 | 61,56 | 61,56 | 53,94 | 57,38 | +0,63% | 12,39% | 698.300 |
| 18/01/2001 | 54,75 | 57,50 | 53,75 | 57,02 | +3,90% | 6,85% | 694.000 |
| 17/01/2001 | 59,38 | 62,25 | 53,88 | 54,88 | -5,18% | 14,11% | 1.732.300 |
| 16/01/2001 | 59,47 | 59,75 | 57,00 | 57,88 | -1,07% | 4,62% | 939.100 |
| 12/01/2001 | 55,88 | 60,50 | 53,50 | 58,50 | +6,12% | 12,53% | 1.337.200 |
| 11/01/2001 | 53,75 | 56,88 | 51,50 | 55,13 | +3,28% | 10,00% | 1.255.500 |
| 10/01/2001 | 46,88 | 55,75 | 46,50 | 53,38 | +11,20% | 19,73% | 1.505.700 |
| 09/01/2001 | 46,88 | 48,88 | 45,19 | 48,00 | +2,13% | 7,87% | 2.120.500 |
| 08/01/2001 | 50,50 | 50,75 | 45,25 | 47,00 | -13,66% | 10,89% | 3.299.600 |
| 05/01/2001 | 60,13 | 60,75 | 52,38 | 54,44 | -9,08% | 13,93% | 2.136.400 |
| 04/01/2001 | 63,00 | 65,50 | 58,56 | 59,88 | -4,39% | 11,01% | 1.410.400 |
| 03/01/2001 | 56,25 | 70,13 | 56,00 | 62,63 | -0,79% | 25,11% | 2.616.600 |
| 02/01/2001 | 71,00 | 72,56 | 62,13 | 63,13 | -11,71% | 14,70% | 1.281.200 |
| 29/12/2000 | 70,94 | 77,13 | 68,50 | 71,50 | +1,06% | 12,16% | 1.021.900 |
| 28/12/2000 | 71,50 | 75,00 | 67,25 | 70,75 | +0,27% | 10,84% | 793.500 |
| 27/12/2000 | 69,00 | 70,75 | 67,13 | 70,56 | +0,18% | 5,25% | 523.200 |
| 26/12/2000 | 72,88 | 72,88 | 68,00 | 70,44 | -2,09% | 6,69% | 501.100 |
| 22/12/2000 | 66,25 | 74,38 | 66,25 | 71,94 | +11,64% | 12,26% | 935.400 |
| 21/12/2000 | 67,75 | 73,50 | 63,00 | 64,44 | -11,73% | 15,50% | 1.878.600 |
| 20/12/2000 | 73,38 | 76,63 | 71,75 | 73,00 | -8,75% | 6,64% | 1.371.400 |
| 19/12/2000 | 80,75 | 83,25 | 78,63 | 80,00 | -1,46% | 5,73% | 1.029.400 |
| 18/12/2000 | 75,91 | 81,44 | 75,63 | 81,19 | +8,61% | 7,66% | 884.600 |
| 15/12/2000 | 74,63 | 75,25 | 70,06 | 74,75 | -0,50% | 6,95% | 1.028.700 |
| 14/12/2000 | 74,31 | 77,63 | 73,06 | 75,13 | -0,91% | 6,14% | 791.500 |